Zimbabwe has turned down a significant American health deal worth $367m (£272m) spanning five years because of Washington's request for confidential information.
The decision came to light after a internal memorandum dated December was disclosed, revealing that President Emmerson Mnangagwa believed the agreement was "lopsided".
An official spokesperson has since clarified that the US was demanding access to genetic material for research and commercial gain but refused to share the benefits from any future treatments.
"We must now begin the difficult and regrettable task of ending our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had provided over $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged more negotiations to secure a deal suitable to both sides so the nation's critical HIV programme can be sustained.
Broader Context
Zimbabwe's decision comes after a comparable case in neighbouring Kenya, where a court halted a similar health funding agreement after legal challenges were filed about the security of Kenyans' medical information.
Since resuming office last year, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
USAID had managed aid for the American government, but Trump stated its expenditure was "wasteful" and his government was seeking direct bilateral agreements to enhance openness and responsibility.
As per reports, 16 African countries have so far agreed to these new agreements, representing more than $18.3bn of fresh investment.
Specifics of the Rejected Agreement
The funds for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this partnership might have yielded significant advantages for Zimbabwean communities, especially the 1.2 million presently receiving HIV treatment through US-supported initiatives," the Ambassador commented.
However, government spokesperson Nick Mangwana maintained the arrangement was "asymmetrical".
"Zimbabwe was being asked to provide its biological resources and data for a long time, without any equivalent promise of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that provided information," Mangwana explained.
"In essence, our nation would provide the raw materials for medical research with no assurance that the end products would be available to our citizens should a new disease outbreak arise."
National Interest and International Frameworks
He also said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one deals were disrupting systems already established through the global health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework designed to deal with potential pandemics.
"This system is intended to ensure that when a country provides its samples, the benefits – including medicines and cures – are shared equitably, not commercialised exclusively by those with the resources to develop them."
The government's concerns regarding the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We are open to continued discussions with our American counterparts on how subsequent co-operation could be arranged in a way that respects the independence and interests of both nations."
Health Experts Response
Medical experts expressed it understood the official position, but suggested that talks need to persist since a large portion of the country's Aids initiatives depended on international support.
"In cases where specific concerns arise, including those involving data governance or implementation frameworks, these can often be addressed through technical clarification and mutually agreed protections," it commented.
The situation underscores the ongoing tensions between receiving crucial international aid and safeguarding a country's data in an increasingly data-driven world.